At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 42 enrolled
Drug / intervention
PF-06882961 20 mgdrug
Likely dose
PF-06882961 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY TO EVALUATE THE PHARMACOKINETICS OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT RENAL IMPAIRMENT
In Brief
A Phase 1 clinical trial evaluating PF-06882961 20 mg for Diabetes Mellitus, Type 2 and 2 related conditions. Completed, enrolled 42 participants across 3 sites.
Detailed Summary
This study will characterize the effect of varying degrees of renal impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose of PF- 06882961 compared with participants with normal renal function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2, Renal Impairment, Healthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartJan 2021
Primary CompletionFeb 2022
TodayJul 2026
First PostedNov 4, 2020
Enrollment StartJan 13, 2021
Primary CompletionFeb 18, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.7 years ago
Interventions
PF-06882961 20 mgdrug
PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1